Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity

Maria Laura Canale; Andrea Camerini; Alda Huqi; Alessio Lilli; Irma Bisceglia; Iris Parrini; Chiara Lestuzzi; Jacopo Del Meglio; Sara Donati; Elio Venturini; Alessandro Sgambato; Luigi Tarantini; Domenico Amoroso; Giancarlo Casolo

doi:10.21873/anticanres.13775

Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity

Maria Laura Canale, Andrea Camerini, Alda Huqi, Alessio Lilli, Irma Bisceglia, Iris Parrini, Chiara Lestuzzi, Jacopo Del Meglio, Sara Donati, Elio Venturini, Alessandro Sgambato, Luigi Tarantini, Domenico Amoroso, Giancarlo Casolo

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND/AIM: Cardiovascular risk factors (CVRFs) predict cardiotoxicity in cancer patients but their role in late cardiac toxicity is less clear.

PATIENTS AND METHODS: This was a retrospective analysis of patients treated with anthracyclines (A) and/or trastuzumab (T) and a correlation with early (≤5 years) or late (>5 years) cardiac toxicity, and baseline CVRFs and CVRFs at toxicity time.

RESULTS: A total of 610 patients were included, 422 with (Group A) and 188 without (Group B) baseline CVRFs. In group A toxicity incidence was 4.7% with all events during treatment or immediately after [mean onset time 0.7 years (range=0.2-1.6)]. Events rate was 3.2% in group B with all events after five years [mean time onset 6.9 years (range=5.2-7.5)]. All group B patients who developed late cardiac toxicity presented with CVRFs at the time of toxicity not reported before.

CONCLUSION: CVRFs could predict late cardiac toxicity and their control should be part of the survivorship program.

Original language	English
Pages (from-to)	5741-5745
Number of pages	5
Journal	Anticancer Research
Volume	39
Issue number	10
DOIs	https://doi.org/10.21873/anticanres.13775
Publication status	Published - Oct 2019

Keywords

Adult
Aged
Anthracyclines/administration & dosage
Antineoplastic Agents, Immunological/adverse effects
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Breast Neoplasms/drug therapy
Cardiotoxicity/etiology
Female
Heart Diseases/chemically induced
Humans
Incidence
Male
Middle Aged
Retrospective Studies
Risk Factors
Trastuzumab/administration & dosage

Access to Document

10.21873/anticanres.13775

Fingerprint Dive into the research topics of 'Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity'. Together they form a unique fingerprint.

Cite this

Canale, M. L., Camerini, A., Huqi, A., Lilli, A., Bisceglia, I., Parrini, I., Lestuzzi, C., Del Meglio, J., Donati, S., Venturini, E., Sgambato, A., Tarantini, L., Amoroso, D., & Casolo, G. (2019). Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity. Anticancer Research, 39(10), 5741-5745. https://doi.org/10.21873/anticanres.13775

Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity. / Canale, Maria Laura; Camerini, Andrea; Huqi, Alda; Lilli, Alessio; Bisceglia, Irma; Parrini, Iris; Lestuzzi, Chiara; Del Meglio, Jacopo; Donati, Sara; Venturini, Elio; Sgambato, Alessandro; Tarantini, Luigi; Amoroso, Domenico; Casolo, Giancarlo.

In: Anticancer Research, Vol. 39, No. 10, 10.2019, p. 5741-5745.

Research output: Contribution to journal › Article › peer-review

Canale, Maria Laura ; Camerini, Andrea ; Huqi, Alda ; Lilli, Alessio ; Bisceglia, Irma ; Parrini, Iris ; Lestuzzi, Chiara ; Del Meglio, Jacopo ; Donati, Sara ; Venturini, Elio ; Sgambato, Alessandro ; Tarantini, Luigi ; Amoroso, Domenico ; Casolo, Giancarlo. / Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity. In: Anticancer Research. 2019 ; Vol. 39, No. 10. pp. 5741-5745.

@article{6dc33538177243fdb328756b3f03e52e,

title = "Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity",

abstract = "BACKGROUND/AIM: Cardiovascular risk factors (CVRFs) predict cardiotoxicity in cancer patients but their role in late cardiac toxicity is less clear.PATIENTS AND METHODS: This was a retrospective analysis of patients treated with anthracyclines (A) and/or trastuzumab (T) and a correlation with early (≤5 years) or late (>5 years) cardiac toxicity, and baseline CVRFs and CVRFs at toxicity time.RESULTS: A total of 610 patients were included, 422 with (Group A) and 188 without (Group B) baseline CVRFs. In group A toxicity incidence was 4.7% with all events during treatment or immediately after [mean onset time 0.7 years (range=0.2-1.6)]. Events rate was 3.2% in group B with all events after five years [mean time onset 6.9 years (range=5.2-7.5)]. All group B patients who developed late cardiac toxicity presented with CVRFs at the time of toxicity not reported before.CONCLUSION: CVRFs could predict late cardiac toxicity and their control should be part of the survivorship program.",

keywords = "Adult, Aged, Anthracyclines/administration & dosage, Antineoplastic Agents, Immunological/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Breast Neoplasms/drug therapy, Cardiotoxicity/etiology, Female, Heart Diseases/chemically induced, Humans, Incidence, Male, Middle Aged, Retrospective Studies, Risk Factors, Trastuzumab/administration & dosage",

author = "Canale, {Maria Laura} and Andrea Camerini and Alda Huqi and Alessio Lilli and Irma Bisceglia and Iris Parrini and Chiara Lestuzzi and {Del Meglio}, Jacopo and Sara Donati and Elio Venturini and Alessandro Sgambato and Luigi Tarantini and Domenico Amoroso and Giancarlo Casolo",

year = "2019",

month = oct,

doi = "10.21873/anticanres.13775",

language = "English",

volume = "39",

pages = "5741--5745",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "10",

}

TY - JOUR

T1 - Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity

AU - Canale, Maria Laura

AU - Camerini, Andrea

AU - Huqi, Alda

AU - Lilli, Alessio

AU - Bisceglia, Irma

AU - Parrini, Iris

AU - Lestuzzi, Chiara

AU - Del Meglio, Jacopo

AU - Donati, Sara

AU - Venturini, Elio

AU - Sgambato, Alessandro

AU - Tarantini, Luigi

AU - Amoroso, Domenico

AU - Casolo, Giancarlo

PY - 2019/10

Y1 - 2019/10

N2 - BACKGROUND/AIM: Cardiovascular risk factors (CVRFs) predict cardiotoxicity in cancer patients but their role in late cardiac toxicity is less clear.PATIENTS AND METHODS: This was a retrospective analysis of patients treated with anthracyclines (A) and/or trastuzumab (T) and a correlation with early (≤5 years) or late (>5 years) cardiac toxicity, and baseline CVRFs and CVRFs at toxicity time.RESULTS: A total of 610 patients were included, 422 with (Group A) and 188 without (Group B) baseline CVRFs. In group A toxicity incidence was 4.7% with all events during treatment or immediately after [mean onset time 0.7 years (range=0.2-1.6)]. Events rate was 3.2% in group B with all events after five years [mean time onset 6.9 years (range=5.2-7.5)]. All group B patients who developed late cardiac toxicity presented with CVRFs at the time of toxicity not reported before.CONCLUSION: CVRFs could predict late cardiac toxicity and their control should be part of the survivorship program.

AB - BACKGROUND/AIM: Cardiovascular risk factors (CVRFs) predict cardiotoxicity in cancer patients but their role in late cardiac toxicity is less clear.PATIENTS AND METHODS: This was a retrospective analysis of patients treated with anthracyclines (A) and/or trastuzumab (T) and a correlation with early (≤5 years) or late (>5 years) cardiac toxicity, and baseline CVRFs and CVRFs at toxicity time.RESULTS: A total of 610 patients were included, 422 with (Group A) and 188 without (Group B) baseline CVRFs. In group A toxicity incidence was 4.7% with all events during treatment or immediately after [mean onset time 0.7 years (range=0.2-1.6)]. Events rate was 3.2% in group B with all events after five years [mean time onset 6.9 years (range=5.2-7.5)]. All group B patients who developed late cardiac toxicity presented with CVRFs at the time of toxicity not reported before.CONCLUSION: CVRFs could predict late cardiac toxicity and their control should be part of the survivorship program.

KW - Adult

KW - Aged

KW - Anthracyclines/administration & dosage

KW - Antineoplastic Agents, Immunological/adverse effects

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

KW - Breast Neoplasms/drug therapy

KW - Cardiotoxicity/etiology

KW - Female

KW - Heart Diseases/chemically induced

KW - Humans

KW - Incidence

KW - Male

KW - Middle Aged

KW - Retrospective Studies

KW - Risk Factors

KW - Trastuzumab/administration & dosage

U2 - 10.21873/anticanres.13775

DO - 10.21873/anticanres.13775

M3 - Article

C2 - 31570476

VL - 39

SP - 5741

EP - 5745

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -